A major pharmaceutical problem is designing diverse and selective lead compounds. The human genome sequence provides opportunities to discover compounds that are protein selective if we can develop methods to identify specificity determinants from sequence alone. We have analyzed sequence and structural diversity of sheep COX-1 and mouse COX-2 proteins by Active Site Profiling (ASP). Eleven residues that should serve as specificity determinants between COX-1 and COX-2 were identified; however, the literature suggests that only one has been utilized in structure-based discovery. ASP was used to create a position-specific scoring matrix, which was used to identify possible cross-reacting proteins from the human sequences. This method proved selective for cyclooxygenases, comparing well with results using BLAST. The methods identify a probable misannotation of a cyclooxygenase in which there is high sequence similarity scores using BLAST, but ASP shows it does not contain the residues necessary for cyclooxygenase function. ASP Analysis of human COX proteins suggests that some specificity determinants that distinguish COX-1 and COX-2 proteins are similar between sheep COX-1/mouse COX-2 and human COX-1/COX2; however, residue identities at those positions are not necessarily conserved. Our results lay groundwork for development of family-specific pattern recognition methods to selectively match compounds with proteins.
A major pharmaceutical problem is designing diverse and selective lead compounds. The human genome sequence provides opportunities to discover compounds that are protein selective if we can develop methods to identify specificity determinants from sequence alone. We have analyzed sequence and structural diversity of sheep COX-1 and mouse COX-2 proteins by Active Site Profiling (ASP). Eleven residues that should serve as specificity determinants between COX-1 and COX-2 were identified; however, the literature suggests that only one has been utilized in structure-based discovery. ASP was used to create a position-specific scoring matrix, which was used to identify possible cross-reacting proteins from the human sequences. This method proved selective for cyclooxygenases, comparing well with results using BLAST. The methods identify a probable misannotation of a cyclooxygenase in which there is high sequence similarity scores using BLAST, but ASP shows it does not contain the residues necessary for cyclooxygenase function. ASP Analysis of human COX proteins suggests that some specificity determinants that distinguish COX-1 and COX-2 proteins are similar between sheep COX-1/mouse COX-2 and human COX-1/COX2; however, residue identities at those positions are not necessarily conserved. Our results lay groundwork for development of family-specific pattern recognition methods to selectively match compounds with proteins.
Introduction. ± Inhibitor Selectivity in Pharmaceutical Drug Discovery. Estimates suggest that current marketed drugs are targeted at less than 500 proteins; however, genomics and proteomics technologies are quickly identifying potential targets with the major goal of determining pharmaceutically relevant targets (proteins) and small molecules that will bind to and modulate the function of these proteins. Recent initiatives, both in the pharmaceutical industry and at the National Institutes of Health, have emphasized the need for molecular diversity in chemo-informatics research, thus recognizing the need for diverse small molecules to more easily identify small molecules that are selective for the target of interest, as well as efficacious. Given that the metric for preparing compounds is diversity as opposed to selectivity, one problem with any collection of diverse small molecules is the potential for activity at a number of binding sites and thus the probability of unwanted toxicity. Having the sequence of the human genome in hand provides the opportunity to identify cross-reacting proteins from the very beginning. To take advantage of this opportunity, methods for rapidly and specifically identifying potentially cross-reacting proteins and quantifying the diversity of their binding sites from sequence information must be developed.
A number of methods for functional site identification based on structural information have been developed [1 ± 5] , and at least one of these has identified limit the invasiveness and metastasis of colon cancer cells [24] . The finding that selective COX-2 inhibitors induce cell cycle arrest and apoptosis in cancer cells through a COX-2-independent mechanism [25] raises the possibility that these agents may act at multiple targets.
The COX proteins provide a good test case for our initial steps in developing methods for identifying functional sites and exploring the diversity of those sites: the family is composed of two different, but very similar, isoforms; inhibitors of these proteins are thought to act at multiple targets; and clinical side effects have resulted in ongoing development of new and more-selective inhibitors. Structural information for this family is limited: only structures for the sheep and mouse proteins have been determined, with different ligands bound. In addition, the number of proteins in this family is small, which allows us to fully characterize results from genome-searching methods. In this paper, we present results from analysis of the structure and chemistry of the COX proteins of known structure, which allows us to explore the structural diversity resulting from ligand binding in these two proteins. We also present results from screening of the human genome sequences with a functional site template developed from the known structures and compare those results to searches based on the full sequence. Our results show differences between subfamilies identified from clustering based on the full-sequence alignment and those clustered based only on active site information, and further suggest a misannotation of one particular COX sequence. The results provide suggestions for specificity determinants at the active site that might allow development of more-selective inhibitors for the COX-1 and COX-2 subfamilies.
Results. ± COX Protein Structures Do Not Represent the Family×s Sequence Diversity. Structures for 17 COX-1 and 8 COX-2 proteins have been solved (Table 1) ; however, this number misrepresents the availability of structural diversity information for these proteins. All of the available COX-2 structures are from the mouse, Mus musculus, and all COX-1 structures are from the sheep, Ovis aries (representative structures are shown in Fig. 1, a and b) . Thus, all structures represent only two protein sequences. Structural differences indicate changes caused by the binding of different ligands (substrates, pseudosubstrates, inhibitors; Table 1 ) to the protein active sites. This limited representation in the PDB will allow us to explore the application of our methods to structural diversity at the active site (in response to ligand binding) but not to sequence diversity.
A multiple sequence alignment of the COX proteins was performed (available as Supplementary Material), and the pairwise identities were calculated (Fig. 2 , below diagonal). As expected, the pairwise sequence identity within each subfamily is 99 ± 100%. (Not all sequences have 100% pairwise identity because of small variations in the constructs used to produce the protein for structure determination.) Between COX-1 and COX-2 isoforms, the pairwise identity is between 61 and 64%. This high sequence identity, in spite of the species difference (sheep vs. mouse), indicates the close relationship between these proteins. As expected, the hierarchical clustering of the full sequence suggests that the isoforms, COX-1 and COX-2, form two distinct subfamilies (Fig. 3, a) ; however, based on this data only, the two large clusters could represent species differences, rather than isoform differences. COX Active Site Profiles Represent Structural Diversity of the Active Site. An active site signature was created for each of the COX proteins, as described in [40] , and the signatures were aligned to create an active site profile (ASP; see Exper. Part). Key functional residues used to create the profile were Tyr 385, which apparently forms the tyrosyl radical that initiates the abstraction of the H pro-S ÀC(13) from the arachidonate [41] [42] ; Arg 120, a residue that coordinates the substrate for H-abstraction [38] ; and Tyr 355, which also coordinates substrate for H-abstraction [38] . The location of the key residues and the selected fragments in the protein structure are shown in Fig. 1 , and the resulting active site profile is shown in Fig. 4 , a. The ASP score, which is based on sequence similarity, for the family, including both COX-1 and COX-2, is 0.45, which is consistent with the pairwise sequence identity (61 ± 64%), between the COX-1 and COX-2 subfamilies. The ASP score for each subfamily is 0.76 for COX-1 and 0.67 for COX-2. Given that, within each family, these sequences are 99 ± 100% identical, one might expect the profile score to be closer to 1; however, as indicated below, some of this represents the structural diversity from binding different ligands. (below the diagonal) and the active site signatures (above the diagonal) for COX proteins for which a structure has been solved (see Table 1 ). The pairwise identities for the COX-1 and COX-2 proteins are highlighted: active site signature identities, light green; full-sequence identities, light yellow.
The pairwise sequence identity of the active site signatures can be compared both between and within the COX-1 and COX-2 subfamilies. Comparison of the pairwise sequence identity between signatures shows that the COX-1 and COX-2 active sites are slightly more similar than the overall protein sequence similarity (compare 51 ± 80% identity for the profiles to 61 ± 64% identity for the overall sequences as shown in Fig. 2 , above the diagonal), with the majority of pairwise identities above 70%. This observation suggests that the functional site sequences have diverged slightly less than the full sequences, indicating a conservation of chemistry and binding determinants. Hierarchical clustering of the active site profile clearly distinguishes the COX-1 and COX-2 subfamilies (Fig. 3, b) . As expected, this indicates that, although similar, the active sites are distinct between the two subfamilies. This is not a phylogenetic or evolutionary analysis of the relationship between these active sites but is meant to illustrate the sequence differences between them.
The comparison within the subfamilies provides a different observation. Within both the COX-1 and COX-2 subfamilies, the pairwise full-sequence identity was 99 ± 100% ( Fig. 2, below diagonal) ; however, the pairwise identity between the active site signatures (within subfamilies) varies from 82 ± 100% (Fig. 2 , above diagonal). This decrease in pairwise identity is not due to differences in sequence; otherwise, these would also be represented in the full-sequence alignments. The lower pairwise identity within each family represents structural divergence at the active site. Changes at the active site cause residues to be included or excluded from the 10-ä radius that defines the signature, which results in a lower pairwise sequence identity when only the signatures are compared. One could imagine possible reasons for structural changes at the active site: changes in crystallization conditions, differences in crystal forms and crystal packing, or differences in ligands bound to the active site under consideration. Examination of the ASP and comparison of the structures around the functional site indicates that the score differences observed here are due to structural effects of the binding and co-crystallization of diverse ligands or inhibitors to the COX active sites. Part of our long-term goal is to identify and quantify differences in the structures of these active sites with the structures of the bound ligands. Fig. 1 for 1cqe and 1cvu. The signatures were aligned using CLUSTALW [43] . a) The three key residues used to define the active site signatures, Tyr 385, Arg 120, and Tyr 355, are colored dark blue. Amino acid residues that are found in continuous fragments from each structure are color-coded to enable visualization. The horizontal line separates the COX-1 from the COX-2 proteins. Colored letters indicate the different fragments or motifs identified in the active site signature. Arrows indicate specific positions where COX-1 and COX-2 proteins differ in sequence at the active site, differences which might indicate specificity determinants in substrate binding and might be used for construction of specific and selective inhibitors. b) LigPlot [44] analysis of the COX active site signatures shows interactions with the crystallographically resolved inhibitors and substrates. Residues in red and blue are involved in H-bonds and hydrophobic interactions, respectively, with the ligand. Two proteins, 1prh [28] and 5cox [37] , although co-crystallized with a ligand, do not provide ligand coordinates and so are not analyzed in this fashion. Several of the analyses show interactions with residues not given in the ASP (mainly for nondrug-like ligands such as arachidonic acid (ACD)). Some of these residues are close in sequence to those found in the ASP, several are not. Arrows indicate those amino acid positions where COX-1 and COXDemonstrating robustness of the clustering used to create Fig. 3 is important if we are to use it as a basis for structural analysis. To determine if the greedy algorithm is locating an optimal or near-optimal solution, hierarchical clustering of COX proteins based on the ASP scoring function with all possible COX combinations was performed. At the third highest level of the cluster tree in Fig. 3 , b, eight COX-2 proteins are grouped into two subsets of two (5cox and 1cx2) and six (1cvu, 1ddx, 4cox, 1pxx, 6cox, and 3pgh). Similarly, 17 COX-1 proteins are grouped into two subsets of ten sequences and seven sequences. Total numbers of combinations for COX-1 and COX-2 subsets are then 19 448 and 28, respectively. All of these combinations were aligned using CLUSTALW, and ASP scores were calculated for each (Fig. 5) , revealing that the greedy hierarchical clustering provides good balance between two groups in both COX-1 and COX-2 by selecting configurations in the upper right quadrant. For COX-1, the hierarchical clustering result is clearly the best choice (being closest to the best-case scenario (1,1) point). For COX-2, the hierarchical clustering result is a very close second. Grouping 3pgh and 1ddx together produces ASP scores of 0.88 and 0.78 respectively, while the hierarchical clustering produces ASP scores of 0.9 and 0.76 for subsets of six and two sequences, respectively. However, the differential is so small that it is hard to argue against using the greedy algorithm for hierarchical clustering, particularly as datasets become larger and exhaustive searches are not be feasible.
Specificity Determinants Can Be Extracted from the Active Site Profile. The active site chemistry with both COX-1 and COX-2 subfamilies is conserved: specific residues important in the chemistry of this protein were identified, and these are conserved across the family (Fig. 4, a) . However, other regions of the active site signatures are not as conserved; thus, specificity determinants, those residues that determine functional specificity between COX-1 and COX-2, should be easily identifiable from the ASP. Eleven positions were identified that are different between the COX-1 and COX-2 proteins (marked by arrows in Fig. 4, a) . The positions of these residues relative to the structure of the active site are shown in Fig. 1, c and d. An analysis of the literature suggests that only one of these differences has been utilized in inhibitor design, the Ile/ Val residue at position 509 [45] .
It is possible that existing ligands take advantage of these specificity determinants but are not mentioned specifically in the literature. To determine if this is so, we performed a LigPlot analysis [44] of the ligands and inhibitors for which we had structures. The hydrophobic contacts and H-bonds formed between the inhibitors and the proteins were mapped to the active site signatures for each protein (Fig. 4, b) . We observe that, of the inhibitors and substrates represented in this structural data set, none take advantage of the specificity determinants identified in the ASP, with the single exception of nine protein ± ligand structures that interact with Ile or Val at position 509. These proteins are identified in Table 1 . Interestingly, of these nine structures, five are substrates or pseudosubstrates, suggesting that the natural ligands interact with residues at this position. Two of the remaining four are co-crystals of the selective inhibitor SC-558, which was identified for its selectivity and ability to interact with this residue position [37] . The other two structures that show interaction with the Ile or Val at this position are 4cox, complexed with indomethacin, and 1q4g, complexed with 1-(1,1'-biphenyl-4-yl)propanoic acid. Indomethacin is a nonselective inhibitor, so, clearly, the interaction with the Val or Ile at this position is not the only determinant required; however, it is an important component to selective inhibitors. One could propose that building ligands that interact with the other specificity determinants identified in Fig. 4 , a might also improve selectivity of the ligands. Human COX Sequences Identified from the Sequence Database. One advantage of having the entire human genome sequence for drug discovery is that it should facilitate identification of all proteins with similar functional sites at the start of a target-lead generation project. Thus, proteins that would potentially cross-react with small molecules could be identified and tested. The active site signatures and profile allow us to focus on the region around the functional site and possible specificity determinants contained therein; thus, we should use this information, not the whole sequence, to search the sequence databases to identify potentially cross-reacting proteins. Towards this end, we recently developed a method, DASP, for using the ASP fragments to build a position-specific scoring matrix (PSSM) [46] to search the sequence databases. As a validation of the method on the COX family, we searched the entire PDB structure database using the ASP PSSM and calculated the Matthews correlation coefficient at each p-value cutoff. Fig. 6 shows that the specificity of this search method for COX proteins is very high above p-values of 10
À5
. We used the ASP PSSM calculated from the ASP shown in Fig. 4 to search the GenBankNR database, hits with a significance score of 10 À4 or better were collected, and the human sequences were selected. The resulting list of 40 proteins is shown in Table 2 ; 27 proteins were previously annotated as cyclooxygenases (or equivalent annotation), and 26 of these had significant (> 10 À5 ) p-values; seven were annotated as transcription factors, and six were annotated as transmembrane channel like proteins with less significant p-values (ca. 10 À5 ). The fragments from the human sequences which aligned with the motifs in the mouse/sheep CHEMISTRY & BIODIVERSITY ± Vol. 2 (2005) 1543 Fig. 6 . The Matthews correlation coefficient is plotted against each p-value cutoff when searching the PDB database using the COX ASP PSSM. Very high selectivity of the ASP-searching method is seen for this family, until a p-value of 10 À5 , where several false positives are identified.
COX ASP were extracted and aligned to create a human COX ASP (Fig. 7) . A full multiple sequence alignment for the human COX sequences is available. We compared the human sequences identified with the ASP PSSM with those identified by a Psi-BLAST search, using both a COX-1 and a COX-2 sequence as the query sequence. Scores for every sequence, including those hit only by the ASP PSSM or only by BLAST, are shown in Table 2 . At high significance scores, BLAST and the ASP PSSM agree completely (white cells in Table 2 ). Two proteins, gi60654447 and gi24430028, were not found in both BLAST searches, but only when using 1cvu as the query sequence; both were found by the ASP PSSM, though gi24430028 was found with a borderline significance score (1.15 Â 10 À5 ; Table 2 ) and is discussed subsequently. There was only one sequence annotated as a COX protein that was identified by BLAST and not by the ASP PSSM, gi46193753, which is annotated as a putative COX-2 (green cell in Table 2 ). To determine why this sequence was not identified by the ASP PSSM, we performed a sequence alignment with it and with the two query sequences used to perform the BLAST search (Fig. 8) . This alignment clearly shows that gi46193753 only contains the N-terminal sequence of a COX protein and is missing most of the required active site residues and, thus, could not function. There are two interpretations of this result: 1) this protein could represent that this sequence is similar to (and probably derived from) the cyclooxygenases; or 2) it could indicate that the sequence contained in GenBank does not represent a full-length sequence (possibly from mistranslation or misidentification of a splice variant). Identification of this sequence indicates one of the advantages of comparing the ASP PSSM and BLAST Fig. 7 . Active site signatures extracted from the GenBank sequences that were identified upon searching GenBank with the PSSM calculated from the ASP shown in Fig. 4 . The lines are consistent with the clusters shown in Fig. 9 , c, with proteins annotated as COX-1 in the top partition, proteins annotated as COX-2 in the second, the two proteins annotated as COX2b and COX-1 in the third partition, the channel-like proteins in the fourth partition, and the transcription factors in the bottom partition. Black arrows indicate possible specificity determinants that would distinguish COX-1 and COX-2 proteins; the red arrow indicates a position that is a specificity determinant in the sheep COX-1/mouse COX-2 proteins, but not in human. The colors indicate the fragments of the sequence that aligned with each motif of the ASP PSSM. The red R, Y, and Y in the top nine sequences are the active site residues used to build the original active site profile (see Fig. 1 ). Fig. 8 . Sequence alignment between COX-1 (1fe2 [36] ), COX-2 (1cvu [38] ), and the one sequence was found by BLAST that was not found by DASP searching GenBankNR: gi j 46193753 j emb j CAG25548.1 j . Fragments contained in the active-site signature for 1CVU and 1FE2 are underlined. Fragments from gi j 46193753 that align with the signature fragments are in bold. Only three fragments that are three residues or longer are found in gi j 46193753, indicating that this sequence (as given) would not catalyze a cyclooxygenase reaction. It is either a fragment or has been translated incorrectly. Multiple sequence alignment was done by CLUSTALW.
results: BLAST identifies overall sequence similarity but does not indicate if the functional residues are maintained.
There is a set of proteins that were identified only by BLAST (18 sequences with scores between 10 À10 and 10 À5 ; pale peach boxes in Table 2 ), or only by the ASP PSSM (13 sequences with p-values of 10 À5 ; light blue and yellow boxes in Table 2 ). None of these sequences are annotated as cyclooxygenases, thus their relationship to the COX family is unclear. The sequences identified by the ASP PSSM fall into two categories: transcription factors (light blue boxes in Table 2 ) and transmembrane channel like proteins (yellow boxes in Table 2 ). None of the residues contains the conserved tyrosines and arginines, so their ability to function as COX proteins is questionable. However, the active site signatures of the channel-like proteins do show striking similarities to the signatures of the actual COX proteins. It will be interesting to observe the structure and function of these proteins when they are determined. It is possible that these sites could cross-react with COX inhibitors, even if they do not function as cyclooxygenases.
Finally, we wanted to compare the clustering of the human sequences identified by the ASP PSSM based on the full-sequence alignment to the clustering based on the ASP; these comparisons are shown in Fig. 9 . Three observations are immediately apparent. First, clustering based on CLUSTALW and ASP scoring functions clearly separates the COX proteins, the channel-like proteins, and the transmembrane proteins (Fig. 9, a and c) , indicating that the differences between these protein families are identifiable within both the full-sequence and active site signatures. Second, the CLUSTALW scoring function clearly separates the proteins annotated as COX-1 and COX-2 into two subfamilies. Using CLUSTALW, gi24430028, the protein annotated as COX-2b, is clustered with the COX-2 proteins, and gi55958154 is clustered with the COX-1 proteins, both consistent with their annotations. Third, using the ASP scoring function to cluster puts gi24430028 and gi55958154 into their own subgroup, outside of the COX-1 and -2 subfamilies (Fig. 9, b and d) . To explore the reasons for this, we analyzed the ASP (Fig. 7) and the full-sequence alignments (Supplementary Material) for these proteins. Both appear to be translations from nucleotide sequence, so their annotations are likely based on a BLAST (or other overall sequence similarity) comparison. Both sequences are missing large parts, including most of the C-terminal one-third of the protein. In both cases, major fragments of the active site are missing, including one of the key tyrosine residues, suggesting that these proteins, as translated, could not function as cyclooxygenases. Again, this could be mistranslations in the sequence database, or they could indicate proteins that are derived from the COX proteins but are now performing other functions. When annotating the function of a protein, these results indicate the importance of performing sequence alignment as well as performing analysis of key functional residues.
Discussion. ± In this contribution, we have compared the sequence and chemistry in the active sites of COX proteins of known structure by calculating active site signatures and an ASP. These proteins, derived only from mouse and sheep proteins, show considerable similarity at their active sites; however, we were able to identify ten residues that are potential specificity determinants between the COX-1 and COX-2 proteins from mouse and sheep. Ideally, these residues would be utilized in lead design to synthesize inhibitors that are selective for the COX-1 and COX-2 subfamilies. Interestingly, a comparison between the specificity determinants identified from the ASP and the actual contacts between known ligands and structures shows that only one of the specificity determinants (Ile/Val 509) has been utilized as a contact in these compounds. We emphasize that we are only able to observe proteins and ligands whose Fig. 9 . Hierarchical clustering of the COX proteins identified by DASP from the GenBank database, with redundant proteins removed to improve readability. The clustering is based on the full sequence and the CLUSTALW [43] scoring function (a and b, resp.), and the ASP and its scoring function (c and d, resp.). In c and d, the lengths of the lines are not representative of the distance between the clusters. The channel-like proteins and transcription factors identified by DASP are outlined with green and dashed-black rectangles, respectively, in a and c; these were removed in b and d to improve readability of the COX clustering. The proteins annotated as COX-1 and COX-2 are grouped into two major subfamilies, outlined by red and blue rectangles, respectively. The protein annotated as COX-2b is marked with a blue arrow; ASP clustering indicates that it is part of the COX-1 family. GI55958154 (red arrow) is annotated as a COX-1, but ASP clustering suggests that it is more like COX-2b.
structures have been identified in this analysis. A future goal of our work is to develop methods for comparing the chemistry and diversity of this small set of compounds to the more than 500 compounds for which binding data to COX proteins are known, but for which structural information is unknown. In drug discovery, the proteins from other organisms, such as mouse and sheep, are used as models, but the ultimate goal is to design drugs that are selective for human proteins. Thus, we used the ASP developed from the mouse and sheep structures to create a PSSM, and search the human genome for related sequences and identified 26 proteins annotated as COX with a significant p-value and one with a less significant pvalue. Comparison of the human COX ASP extracted from these proteins allows us to compare the specificity determinants between human COX-1 and COX-2 proteins, and the sheep COX-1 and mouse COX-2 proteins. Seven positions that potentially serve as specificity determinants between the human COX-1 and COX-2 proteins are indicated by the arrows in Fig. 7 . Comparison of these positions to those in the sheep and mouse proteins (arrows, Fig. 4) indicates that often the positions of the specificity determinants are conserved, but that the identity of the residues at those positions is less conserved. Three of the observed specificity determinants are conserved both in position and residue identity (Leu/Tyr; Ser/Val; and Phe/His). Three positions are conserved in position but not identity (Asn/Tyr, Gln/Thr, and Met/Leu in sheep COX-1/mouse COX-2, and Asn/His, His/Thr, and Ile/Val in human COX-1/COX-2). One position is a specificity determinant in the sheep and mouse proteins but not the human proteins (Gln/His in sheep/mouse vs. His/His human COX-1/COX-2). Finally, one position is a specificity determinant in human but not the sheep/mouse proteins (Leu in both sheep and mouse proteins vs. Tyr/Leu in human COX-1/COX-2). The ASP analysis simplifies the analysis and comparison of these specificity determinants.
In the search of GenBank using the COX ASP PSSM, we also identified seven proteins annotated as transcription factors and six annotated as transmembrane channel like proteins, though these had less significant p-values than any identified COX. None of these proteins includes the conserved Arg, Tyr, and Tyr necessary for cyclooxygenase function, but could be potential sites of cross-reactivity for inhibitors. This finding and the analysis of these results will be the focus of future research.
Active site profiling allows us to focus on the region of the protein that should contain the determinants for specific and selective binding of substrates and inhibitors. The results described here provide the groundwork necessary to allow us to develop methods by which we can analyze the specificity determinants for any binding site for which a structure is known. Using a small amount of known structural information from other species, we can identify potential cross-reacting proteins from the human proteins and residues ± the so-called specificity determinants ± which should allow design of selective inhibitors across any protein family. We will use these methods to develop pattern recognition methods to match small molecules to these active sites, with emphasis on design at the positions of the specificity determinants, so that we can improve the development of diverse and selective lead compounds.
Experimental Part
Protein Data Sets. Seventeen COX-1 and eight COX-2 protein structures have been solved and have had their coordinates deposited in the PDB database ( Table 1 ) [26] . The sequence data base searched was the nonredundant sequence database at GenBank; human sequences were extracted from all sequences that were found.
Construction of Active Site Signatures and Profile. The active site signatures of the 25 COX structures were constructed as described in [40] ; the following key functional residues were identified: Tyr 385, Arg 120, and Tyr 355. Any residue that contains an atom located within 10 ä of the center of mass of these key residues was identified. Fragments of each protein sequence that fall within these spheres were extracted and concatenated from N-to C-terminus to create the active site signature for each structure. Signatures were aligned using CLUSTALW [43] to create the complete active site profile (ASP). An ASP score is based only on sequence information and is calculated using positive weights for sequence identity and similarity, and negative weights for gaps [40] .
Using the Active Site Profile to Search Sequence Databases. To search a sequence database for matches to an ASP, we must first determine the ASP motifs. We define the motifs as those fragments located within the active site signature (marked as yellow ribbons in Fig. 1 ). Position-specific scoring matrices (PSSMs) are created for each motif and used to search all sequences of the database using a sliding window procedure [46] . The scores of all matches are then evaluated for statistical significance. To identify the motifs, the ASP is traversed from left to right searching for fragments that align. If fragments, or portions of fragments, are identified at position i in the alignment, then the shortest (least number of residues) such fragment, f, provides the bounds for the prospective motif. We only consider fragments of at least three residues in length, since considering shorter fragments could result in insignificant matches when querying database sequences. It would not be correct, for example, to identify a one-residue motif because any query sequence (most likely) will match this motif perfectly. A motif is identified at i if the majority of the sequences in the profile have a fragment or a portion of a fragment between i and j, with j being the position in the profile where the fragment ends. Note that all sequences may not be included in every motif of the profile. The search then begins again, using residue j 1 as residue i, in the same manner. Once all motifs in the profile have been identified, individual multiple sequence alignments (MSAs) are created for each motif.
PSSMs are created from MSAs by iterating over the columns of the MSA and tallying the observed counts and the pseudocounts for each residue [46] . The observed counts are taken by simply recording the number of occurrences of each residue in the current column; the pseudocounts are based on the overall frequency of the amino acid in the background database. Both counts for each residue are then summed and normalized by the sum of the number of columns in the MSA and the pseudocount weight. Once the PSSMs are created from the MSA of each motif, a sequence database can be searched for statistically significant matches. Each of the n PSSMs is matched to each of the m sequences of the database, resulting in a score. Each score represents how well the sequence matches the motif. Using previously described methods [47] , for each score, a p-value is obtained, normalized for the length of the sequence and motif, and multiplied to obtain a product. The product is input to the QFAST algorithm, which produces an overall p-value for the match of the sequences to the active site profile [47] .
The set of true positives for each family was determined by using Psi-Blast ( [48] , http://www.ncbi.nlm.-nih.gov/BLAST) to be sure we had identified all true positive COX proteins in the PDB. The PSSM calculated from the ASP for each COX-1 and COX-2 subfamily was used to search against the PDB using a series of pvalue thresholds to determine positive matches. After a database search for a family was completed, the Matthews correlation coefficient for the search was computed. The Matthews correlation coefficient [49] is a measure of how well an algorithm performs, factoring in the true positives, true negatives, false positives, and false negatives.
Hierarchical Clustering and Determination of Robustness. In a hierarchical clustering procedure, a nested set of clusters is created, with each level in the hierarchy representing a set of clusters. At the lowest level, each item (protein in this case) belongs to its own cluster, while, at the highest level, all items belong to one larger cluster. The number of clusters is not required as an input parameter to hierarchical clustering.
We conducted two independent runs of hierarchical clustering analyses: one on the ASPs using the ASP scoring function, and one on the full sequences using CLUSTALW and its own scoring function. Our clustering algorithm is greedy in that we invoke optimal pairwise clustering at each level without regard to the optimality of the final clustering. While an exhaustive search is computationally feasible for our current data (and was in fact performed to give credence to our result and is described later), it will not be so for larger data sets. In the ASP clustering, a pairwise alignment is first performed among all active site sequences, and the ASP score for each pair is calculated. The sequence pair with the highest score is clustered first. If multiple pairs have the same score, then multiple clusters are formed at that level. If one sequence is included in multiple pairs, it is clustered with the first sequence among all sequences it shares the highest score with in a sequential order. The newly formed clusters are now treated as a single item at the next clustering level. The process is repeated until all sequences are grouped in one cluster. A dendrogram is created at the end of clustering to illustrate the different sets of clusters. To cluster the full sequences, a complete MSA is created using CLUSTALW [43] . A neighborjoining algorithm [50] is used to construct a phylogenetic tree from the MSA. A phylogenetic tree is assumed to be an estimate of a phylogeny, so the branch lengths are proportional to the evolutionary distance between the sequences.
LigPlot Analysis of Binding Sites. Using the default bond and distance settings within LigPlot [44] , the ligand ± protein interactions for (if multiple chains were represented) chain A were analyzed. The interactions calculated by LigPlot were displayed both in the LigPlot-type plots and text files and analyzed manually. The residues present in the ASP which were shown to interact with the ligand(s) from the LigPlot analyses were then classified by interaction type. Interacting residues not in the ASP were identified.
BLAST Search for COX Sequences in GenBankNR. The sequences found in GenBank by our sequence searching method were compared with those identified by BLAST. The FASTA sequence for each of COX-1 and COX-2 (taken from 1fe2 [36] and 1cvu [38] , resp.) were used to search the protein sequence databases using three iterations of Psi-Blast ( [48] , http://www.ncbi.nlm.nih.gov/BLAST). The human nr database was searched using a 0.01 expectation value as the cutoff. We compared the results of the ASP search to these BLAST results.
